Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines.
- Published In:
- Molecular therapy. Nucleic acids, 36(3), 102623 (2025)
- Authors:
- Zhou, Shurong, Liang, Yuqing, Hao, Yu, Wang, Qiyan, Xu, You, Su, Ting, Cheng, Furong, Zhu, Guizhi
- Database ID:
- RPEP-14626
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14626APA
Zhou, Shurong; Liang, Yuqing; Hao, Yu; Wang, Qiyan; Xu, You; Su, Ting; Cheng, Furong; Zhu, Guizhi. (2025). Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines.. Molecular therapy. Nucleic acids, 36(3), 102623. https://doi.org/10.1016/j.omtn.2025.102623
MLA
Zhou, Shurong, et al. "Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines.." Molecular therapy. Nucleic acids, 2025. https://doi.org/10.1016/j.omtn.2025.102623
RethinkPeptides
RethinkPeptides Research Database. "Combined cancer immunotherapy with lipid nanoparticle delive..." RPEP-14626. Retrieved from https://rethinkpeptides.com/research/zhou-2025-combined-cancer-immunotherapy-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.